{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T10:40:41Z","timestamp":1769078441865,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-09993-8","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T08:01:38Z","timestamp":1728288098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Bedaquiline versus injectable containing regimens for rifampicin-resistant and multidrug-resistant tuberculosis in a reference center in Brazil \u2013 a real-world evidence study using a retrospective design"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5226-4372","authenticated-orcid":false,"given":"Ana Paula","family":"Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9977-063X","authenticated-orcid":false,"given":"Crist\u00f3v\u00e3o Jorge","family":"Benace Jr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6015-9628","authenticated-orcid":false,"given":"Janaina Aparecida","family":"de Medeiros Leung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5900-6007","authenticated-orcid":false,"given":"Afr\u00e2nio Lineu","family":"Kritski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3250-6738","authenticated-orcid":false,"given":"Fernanda Carvalho","family":"de Queiroz Mello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"9993_CR1","unstructured":"The Global Plan to End TB 2023\u20132030. Geneva, Switzerland. Stop TB Partnership. 2022. Available: file:\/\/\/C:\/Users\/Z728352\/Downloads\/global_plan_to_end_tb_2023\u20132030.pdf"},{"key":"9993_CR2","volume-title":"Licence: CC BY-NC-SA 3.0 IGO","author":"Global tuberculosis report 2023","year":"2023","unstructured":"Global tuberculosis report 2023. Licence: CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization; 2023."},{"key":"9993_CR3","unstructured":"WHO treatment guidelines for drug-resistant tuberculosis, WHO\/HTM\/TB\/2016.04. 2016 update. http:\/\/apps.who.int\/iris\/bitstream\/10665\/250125\/1\/9789241549639-eng.pdf?ua=1. World Health Organization: 2016."},{"issue":"8","key":"9993_CR4","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","volume":"371","author":"AH Diacon","year":"2014","unstructured":"Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, TMC207-C208 Study Group, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723\u201332.","journal-title":"N Engl J Med"},{"key":"9993_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.tube.2019.06.005","volume":"117","author":"H Patel","year":"2019","unstructured":"Patel H, Pawara R, Pawara K, Ahmed F, Shirkhedkar A, Surana S. A structural insight of bedaquiline for the cardiotoxicity and hepatotoxicity. Tuberculosis. 2019;117:79\u201384.","journal-title":"Tuberculosis"},{"issue":"2","key":"9993_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/13993003.00724-2015","volume":"47","author":"AS Pym","year":"2016","unstructured":"Pym AS, Diacon AH, Tang SJ, Conradie F, Danilovits M, et al. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur Respir J. 2016;47(2):564\u201374.","journal-title":"Eur Respir J"},{"key":"9993_CR7","doi-asserted-by":"publisher","first-page":"200330","DOI":"10.1183\/13993003.03300-2020","volume":"57","author":"F Mirzayev","year":"2021","unstructured":"Mirzayev F, Viney K, Linh NN, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update. Eur Respir J. 2021;57:200330.","journal-title":"Eur Respir J"},{"key":"9993_CR8","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.5588\/ijtld.20.0048","volume":"24","author":"N Padayatchi","year":"2020","unstructured":"Padayatchi N, Bionghi N, Osman F, Naidu N, Ndjeka N, Master I, et al. Treatment outcomes in patients with drug-resistant TB-HIV co-infection treated with bedaquiline and linezolid. Int J Tuberc Lung Dis. 2020;24:1024\u201331.","journal-title":"Int J Tuberc Lung Dis"},{"key":"9993_CR9","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijid.2021.08.055","volume":"111","author":"L Fu","year":"2021","unstructured":"Fu L, Weng T, Sun F, Zhang P, Li H, Li Y, et al. Insignificant difference in culture conversion between bedaquiline-containing and bedaquiline-free all-oral short regimens for multidrug-resistant tuberculosis. Int J Infect Dis. 2021;111:138\u201347.","journal-title":"Int J Infect Dis"},{"key":"9993_CR10","first-page":"239","volume":"44","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Xiong Y, Chang T, Liu F. Analysis of adverse reactions of bedaquiline containing regimen in the treatment of drug-resistant pulmonary tuberculosis. Chin J Antituberc. 2022;44:239\u201345.","journal-title":"Chin J Antituberc"},{"key":"9993_CR11","volume-title":"Nota Informativa N\u00ba 9\/2021. Atualiza\u00e7\u00e3o das recomenda\u00e7\u00f5es do tratamento da tuberculose drogarresistente com a disponibiliza\u00e7\u00e3o da bedaquilina e delamanida","author":"Brasil","year":"2021","unstructured":"Brasil. Minist\u00e9rio Da Sa\u00fade. Departamento De Vigil\u00e2ncia em Sa\u00fade. Departamento De Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis. Coordena\u00e7\u00e3o-Geral do Programa Nacional De Controle Da Tuberculose. Nota Informativa N\u00ba 9\/2021. Atualiza\u00e7\u00e3o das recomenda\u00e7\u00f5es do tratamento da tuberculose drogarresistente com a disponibiliza\u00e7\u00e3o da bedaquilina e delamanida. Bras\u00edlia: Minist\u00e9rio da Sa\u00fade; 2021."},{"issue":"2","key":"9993_CR12","first-page":"e2018158","volume":"28","author":"P Bartholomay","year":"2019","unstructured":"Bartholomay P, Pinheiro RS, Pelissari DM, Arakaki-Sanchez D, Dockhorn F, Rocha JL, et al. Special Tuberculosis Treatment Information System (SITE-TB) in Brazil: background, description and perspectives. Epidemiol Serv Saude. 2019;28(2):e2018158.","journal-title":"Epidemiol Serv Saude"},{"key":"9993_CR13","unstructured":"World Health Organization. Meeting Report of the WHO Expert Consultation on Drug-resistant tuberculosis treatment outcome definitions, 17\u201319 November 2020. Geneva, World Health Organization,; 2021."},{"key":"9993_CR14","doi-asserted-by":"publisher","first-page":"100405","DOI":"10.1016\/j.jctube.2023.100405","volume":"34","author":"O Ur Rehman","year":"2023","unstructured":"Ur Rehman O, Fatima E, Ali A, Akram U, Nashwan A, Yunus F. Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: an updated systematic review and meta-analysis. J Clin Tuberc Other Mycobact Dis. 2023;34:100405.","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"issue":"5","key":"9993_CR15","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.pulmoe.2021.02.006","volume":"27","author":"S Koirala","year":"2021","unstructured":"Koirala S, Borisov S, Danila E, Mariandyshev A, Shrestha B, Lukhele N, et al. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: results from a large global cohort. Pulmonology. 2021;27(5):403\u201312.","journal-title":"Pulmonology"},{"issue":"10","key":"9993_CR16","doi-asserted-by":"publisher","first-page":"e1380","DOI":"10.1016\/S2214-109X(21)00300-4","volume":"9","author":"L Chenciner","year":"2021","unstructured":"Chenciner L, Annerstedt KS, Pescarini JM, Wingfield T. Social and health factors associated with unfavourable treatment outcome in adolescents and young adults with tuberculosis in Brazil: a national retrospective cohort study. Lancet Glob Health. 2021;9(10):e1380\u201390.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"9993_CR17","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1038\/s41598-020-62667-8","volume":"10","author":"P Nguipdop-Djomo","year":"2020","unstructured":"Nguipdop-Djomo P, Rodrigues LC, Smith PG, Abubakar I, Mangtani P. Drug misuse, tobacco smoking, alcohol and other social determinants of tuberculosis in UK-born adults in England: a community-based case-control study. Sci Rep. 2020;10(1):5639.","journal-title":"Sci Rep"},{"issue":"13","key":"9993_CR18","doi-asserted-by":"publisher","first-page":"7721","DOI":"10.3390\/ijerph19137721","volume":"19","author":"AR Scholze","year":"2022","unstructured":"Scholze AR, Alves JD, Berra TZ, Ramos ACV, Pieri FM, Pillon SC, et al. Tuberculosis among people living on the Street and using Alcohol, Tobacco, and illegal drugs: analysis of territories in Extreme Vulnerability and trends in Southern Brazil. Int J Environ Res Public Health. 2022;19(13):7721.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"9993_CR19","doi-asserted-by":"publisher","first-page":"e20180075","DOI":"10.1590\/1806-3713\/e20180075","volume":"45","author":"MTG Savioli","year":"2019","unstructured":"Savioli MTG, Morrone N, Santoro I. Primary bacillary resistance in multidrug-resistant tuberculosis and predictive factors associated with cure at a referral center in S\u00e3o Paulo, Brazil. J Bras Pneumol. 2019;45(2):e20180075.","journal-title":"J Bras Pneumol"},{"issue":"20","key":"9993_CR20","doi-asserted-by":"publisher","first-page":"10678","DOI":"10.3390\/ijerph182010678","volume":"18","author":"MY Teferi","year":"2021","unstructured":"Teferi MY, El-Khatib Z, Boltena MT, Andualem AT, Asamoah BO, Biru M, Adane HT. Tuberculosis treatment outcome and predictors in Africa: a systematic review and Meta-analysis. Int J Environ Res Public Health. 2021;18(20):10678.","journal-title":"Int J Environ Res Public Health"},{"key":"9993_CR21","doi-asserted-by":"publisher","first-page":"e178","DOI":"10.26633\/RPSP.2020.178","volume":"44","author":"M Bhering","year":"2020","unstructured":"Bhering M, Kritski A. Primary and acquired multidrug-resistant tuberculosis: predictive factors for unfavorable treatment outcomes in Rio De Janeiro, 2000\u20132016. Rev Panam Salud Publica. 2020;44:e178.","journal-title":"Rev Panam Salud Publica"},{"key":"9993_CR22","doi-asserted-by":"publisher","first-page":"1151077","DOI":"10.3389\/fpubh.2023.1151077","volume":"11","author":"M Birhane","year":"2023","unstructured":"Birhane M, Mekonnen S, Dingeta T, Teklemariam Z. Loss to follow-up tuberculosis treatment and associated factors among adults attending at public health facilities in Warder District, Somali Regional State, Eastern Ethiopia. Front Public Health. 2023;11:1151077.","journal-title":"Front Public Health"},{"issue":"12","key":"9993_CR23","doi-asserted-by":"publisher","first-page":"e0261152","DOI":"10.1371\/journal.pone.0261152","volume":"16","author":"P Mishra","year":"2021","unstructured":"Mishra P, Sharma RK, Yadav R, Rao VG, Nigam S, Lingala MA, Bhat J. Reasons for loss to follow-up (LTFU) of pulmonary TB (PTB) patients: a qualitative study among Saharia, a particularly vulnerable tribal group of Madhya Pradesh, India. PLoS ONE. 2021;16(12):e0261152.","journal-title":"PLoS ONE"},{"key":"9993_CR24","doi-asserted-by":"publisher","first-page":"1701462","DOI":"10.1183\/13993003.01462-2017","volume":"50","author":"E Pontali","year":"2017","unstructured":"Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J. 2017;50:1701462.","journal-title":"Eur Respir J"},{"issue":"2","key":"9993_CR25","doi-asserted-by":"publisher","first-page":"e20210384","DOI":"10.36416\/1806-3756\/e20210384","volume":"48","author":"H Hatami","year":"2022","unstructured":"Hatami H, Sotgiu G, Bostanghadiri N, Abadi SSD, Mesgarpour B, Goudarzi H, et al. Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Bras Pneumol. 2022;48(2):e20210384.","journal-title":"J Bras Pneumol"},{"key":"9993_CR26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.3390\/antibiotics12091389","volume":"12","author":"E Tong","year":"2023","unstructured":"Tong E, Wu Q, Chen Y, Liu Z, Zhang M, Zhu Y, Wu K, Pan J, Jiang J. The efficacy and safety of Bedaquiline in the treatment of pulmonary tuberculosis patients: a systematic review and Meta-analysis. Antibiotics. 2023;12:1389.","journal-title":"Antibiotics"},{"key":"9993_CR27","doi-asserted-by":"publisher","first-page":"2002544","DOI":"10.1183\/13993003.02544-2020","volume":"57","author":"D Chesov","year":"2021","unstructured":"Chesov D, Heyckendorf J, Alexandru S, et al. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J. 2021;57:2002544.","journal-title":"Eur Respir J"},{"issue":"2","key":"9993_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/0253-7613.178839","volume":"48","author":"J Charan","year":"2016","unstructured":"Charan J, Reljic T, Kumar A. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: a systematic review. Indian J Pharmacol. 2016;48(2):186\u201391.","journal-title":"Indian J Pharmacol"},{"issue":"9","key":"9993_CR29","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1093\/cid\/ciz1107","volume":"71","author":"RR Kempker","year":"2020","unstructured":"Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, Bablishvili N, et al. Clinical outcomes among patients with drug-resistant tuberculosis receiving bedaquiline- or delamanid-containing regimens. Clin Infect Dis. 2020;71(9):2336\u201344.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"9993_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4103\/ijmy.ijmy_217_22","volume":"12","author":"ON Putra","year":"2023","unstructured":"Putra ON, Yulistiani Y, Soedarsono S, Subay S. Favorable outcome of individual regimens containing bedaquiline and delamanid in drug-resistant tuberculosis: a systematic review. Int J Mycobacteriol. 2023;12(1):1\u20139.","journal-title":"Int J Mycobacteriol"},{"issue":"1","key":"9993_CR31","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s12879-021-05947-6","volume":"21","author":"NF Sabur","year":"2021","unstructured":"Sabur NF, Brar MS, Wu L, Brode SK. Low-dose amikacin in the treatment of Multidrug-resistant tuberculosis (MDR-TB). BMC Infect Dis. 2021;21(1):254.","journal-title":"BMC Infect Dis"},{"key":"9993_CR32","volume-title":"Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update","author":"WHO consolidated guidelines on tuberculosis","year":"2022","unstructured":"WHO consolidated guidelines on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09993-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09993-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09993-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T05:01:00Z","timestamp":1732856460000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09993-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9993"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09993-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"31 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was submitted to Clementino Fraga Filho \u2013 UFRJ Ethics Committee and was approved under # 5.959.943. Because of the retrospective design of the study and the total anonymity of patient\u2019s identification, the IRB mentioned above waived the need of informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1112"}}